| INTRODUCTION
Candida bloodstream infections (BSIs) are increasingly common worldwide in intensive care units (ICUs) and are the third most common cause of nosocomial BSIs among critically-ill ICU patients.
1,2 Although culture-directed (proven, defined as patients with a diagnostic confirmation of a fungal infection) antifungal therapy provides specific pathogen and susceptibility results for targeted therapy, the wait for a positive result is considered unsatisfactory because of its association with high crude mortality rates and substantial excess costs. 3 To improve outcomes, early antifungal intervention strategies are increasingly being considered. 3 Such strategies include prophylaxis (defined as treatment to prevent fungal infections in high-risk patients), preemptive (defined as initiation of antifungal treatment in patients suspected of a fungal infection but without the diagnostic confirmation of fungal infection), and empiric therapy (defined as antifungal treatment given to patients with fever of unknown origin, which was not responding to broad spectrum antibacterial therapy).
Defining the patient populations that would benefit from early antifungal treatment remains a challenge. 4, 5 Colonisation with Candida spp. precedes infection and, in conjunction with other known risks factors, may be an early predictor of candidaemia. [6] [7] [8] In practice, in an attempt to decrease Candida-related morbidity and mortality, an increasing number of patients in ICUs without documented candidaemia receive early antifungal therapy based on the presence of specific risk factors. [9] [10] [11] [12] [13] [14] [15] [16] The identification of appropriate antifungal therapy for patients in
ICUs with sepsis and Candida colonisation also remains a challenge.
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Studies have shown that inappropriate antifungal treatment (e.g. resistance to the antifungal agent, inadequate drug dosage or delayed therapy) is related to worse clinical outcomes, increased length of stay (LOS) and increased associated costs compared with appropriate treatment. [17] [18] [19] In a cost-containment environment, clinicians are expected to choose the optimal strategy to provide appropriate antifungal therapy while controlling costs. However, to our knowledge, there is limited information on the cost of antifungal therapy for proven candidiasis compared with cost of early antifungal therapy for patients without documented candidaemia. Data regarding physicians' choices for specific antifungal therapy and related costs in Greece are also lacking.
We conducted this study to assess the impact on overall hospital costs of different strategies for systemic antifungal therapy (SAT) in patients in Greek ICUs, and to identify clinical factors that may affect these costs.
| MATERIALS AND METHODS

| Study design
This prospective, multicentre, non-interventional study (NIS) of patients receiving SAT was carried out in compliance with the protocol, 
| Outcomes
The primary study objectives were to provide an estimate of the total ICU treatment cost for patients receiving SAT, from the Greek social insurance perspective, and to describe the different therapeutic approaches of antifungal treatment and their association with treatment effectiveness. The present manuscript summarises the total ICU treatment cost and the clinical factors that directly affect this cost.
SAT strategy was €20 458 (proven), €15 054 (prophylaxis), €23 594 (empiric) and 
| Data collection
The study data were recorded on an electronic data capture system for subsequent analysis. 
| Statistical analysis
Sample size calculation was based on a one-sample mean test (twosided at 5% significance level with 90% power), where a range of possible values for the mean total cost under H o (€10 000-€40 000) and the mean total cost under H 1 (€15 000-€50 000) was assessed. Standard deviation (SD) ranged from €15 000-€37 000. The maximum required sample size of the tested scenarios was 152 patients. Since this was an ICU study where the dropout rate was expected to be minimal, there was a minor adjustment to the sample size for drop outs to 160 patients.
Prior to the application of the multivariate analyses, specific univariate analyses were performed with the Kruskal-Wallis test (the non-categorical factors were categorised based on their distributional profile) to identify important bivariate correlations. Data were analysed using a step-wise multiple regression model including, at the beginning, all factors found to be statistically significantly (at the 5% level of significance) correlated with total cost (cost of LOS was excluded since it was the major cost component) in the univariate analysis.
Statistical significance for the factors remaining in the model was declared at the 10% level using backward selection. Several adjustment factors were included in the model regardless of statistical significance (APACHE II score, patient's origin, first line SAT, survival status at the end of the ICU stay and study site). All analyses were performed using SAS ® version 9.2 (SAS Institute Inc., Cary, NC, USA).
| RESULTS
| Patients
In total, 155 patients receiving SAT as instructed by the lead physician were included in the study ( 
| Antifungal treatment
Total ICU patients days studied were 5766 of which 1891 (32.8%)
were days when antifungal therapy was administered. Antifungal strategy, day of treatment initiation and duration of therapy, are shown in Table 2 . The mean number of days for antifungal treatment to be initiated was 12.9±22.4 days. In all strategies, the most frequently prescribed antifungal drugs were echinocandins (n=89; 57.4%), followed by fluconazole (n=31; 20%), itraconazole (n=20;
12.9%), liposomal amphotericin B (n=7; 4.5%), voriconazole (n=5;
3.2%) and amphotericin B (n=3; 2%). Initial antifungal treatment was modified in 13/155 (8.4%) patients due to resistance or clinical failure; these patients were initially treated with fluconazole or itraconazole (n=7), an echinocandin (n=3) or liposomal amphotericin B (n=3). Seven patients had a de-escalation of antifungal therapy (treatment initiation before switching to a more narrow spectrum drug) governed by subsequent susceptibility results. 
| Outcomes
| Costs
Mean total cost per patient was €22 013 (95% CI: €19 553-€24 472)
with SD €15 500 (95% CI: €13 945-€17 447). LOS was the major cost component with a mean value of €17 787 ( Figure 1 ). Cost per patient by type of treatment is shown in Table 4 . For the 155 patients in this study, associated antifungal drug costs accounted for €0.57 million (16.7%) of the €3.4 million total costs.
In the univariate analysis there was no statistically significant difference in cost between different strategies, although prophylaxis was associated with a €7000 decrease in total cost (mean €15 054). Additionally, there were no statistically significant differences among the different strategies in daily total and antifungal drug costs. Table 5 ). The effect of the different study drugs on cost is shown in Figure 2 .
| DISCUSSION
The most important finding from our study was that the administration of an antifungal drug was not a substantial component of total reports that inappropriate antifungal therapy is related to worse clinical outcomes and to an escalation in cost due to prolonged LOS. 17, 19 Others showed that inappropriate antifungal treatment prolonged LOS by 8 days, and contributed an extra $13 000 to total costs and increased mortality (28.8% vs 0%). 22 Therefore choosing an appropriate first-line antifungal agent is crucial for better outcomes, reduced LOS and lower hospital cost of managing candidiasis.
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An important distinction from our study is that the duration of previous ICU-LOS is an important contributor of total LOS and overall cost. Also, antifungal therapy was started a mean of 12.9±22.4 days after ICU admission, suggesting that earlier administration of antifungal therapy may be appropriate, especially in patients with a high APACHE II score. In accordance with our findings, another study found that each additional day lag prior to initiating SAT therapy for aspergillosis was associated with 1.28 days longer LOS and a 4% increase in total cost. 26 Others have shown the mean pre-ICU-LOS may be a significant risk factor for the development of candidaemia and subsequent increase to the costs of care. 27 These findings support the need for more rapid diagnostic methods for IC in ICU patients and earlier initiation of antifungal therapy. In critically ill patients, there should always be a high degree of suspicion that IC may occur.
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In our study, the APACHE II score used as an adjustment covariate had a negative association with total cost indicating that severely ill patients with a high APACHE II score had higher early mortality and lower LOS and ICU care, which decreased total cost. Baddley et al., [26] which excluded patients with early mortality, found that severity of illness (extreme vs major) was associated with a 57% increase in hospital costs. 26 Numerically more patients died in the non-switching group, which could account for the shorter LOS and treatment duration. Others reported that a high APACHE II score contributed to total cost and Candida infections were associated with a cost of $230/ICU/ patient-day and an increased ICU-LOS of 8 days. 28 Thus, the mortality adjusted APACHE II effect analysis showed that an increased score was a significant contributor of total cost, as might be expected, since more severely ill patients require prolonged or specific care.
It is well documented that fever is associated with illness severity and mortality. 29, 30 Indeed, patients with febrile septic shock who receive external cooling to achieve normothermia have significantly decreased vasopressor dose requirements after 12 h of treatment (P<.001) and lower 14-day mortality (P=.013) and shock reversal is also more common (P=.021) vs those whose fever is untreated, inferring that persistent fever is related to increased cost due to increased duration of shock.
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The mean total cost in our study population receiving antifungal therapy was €22 013 (SD 15 500). Our findings in patients receiving antifungal treatment are similar to other studies, which reported costs associated with candidaemia of between $25 000 and $55 000. 28, [32] [33] [34] [35] [36] [37] [38] [39] [40] We identified that candidaemia may affect total costs for patients receiving antifungal therapy. This may have several explanations including the need for prolonged antifungal therapy until resolution of candidaemia (mean duration of antifungal therapy in proven before treatment vs unproven candidaemia was 13.2±10. Limitations of our study include that the study was not a randomised clinical trial aiming to draw causal relationships. However, it is an observational real life study reflecting clinical practice, the value of each therapeutic approach and related total costs. In such a real life study with a subjectively selected group of ICU patients, the observed values of actual and predicted mortality, as well as the accuracy of the Candida score cannot be compared with the results of large epidemiological studies.
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Furthermore, because all participating ICUs were in Greece, the effect of SAT on costs may not reflect clinical practice in other countries and inter-country differences in ICUs. Therefore several other local factors that may influence LOS and costs in different ICUs cannot be excluded.
In conclusion, we found that the most important clinical factors affecting cost were switching treatment (due to failure of initial treatment), presence of fever, diagnosis of candidaemia, previous antifungal use and ICU-LOS. Accordingly, strategies that decrease ICU-LOS and improve the earlier selection of appropriate antifungal agents in antifungal strategies should be prioritised in order to decrease the costs for patients receiving SAT. In accordance with the literature, these findings highlight the importance of awareness of potential candidiasis, timely diagnosis and appropriate early treatment of ICU patients in order to improve patient outcomes while containing direct medical costs. Further research including cost effectiveness and budget impact analysis is warranted.
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